NEW YORK AND LONDON
Celsus Therapeutics Plc (NASDAQ:CLTX), an emerging growth, development-stage biotech company, today announced its financial results and provided a review of the twelve month period ended December 31, 2013.
A Revolution in Treating Autoinflammatory & Orphan Diseases